| The PARTNER 3 and Evolut Low Risk trials will greatly expand the use of TAVR to a significantly larger group of eligible patients with severe aortic stenosis. |
| SAVR remains a vital treatment choice in patients with high anatomical risk including bicuspid aortic valve, heavy annular calcification, and low coronary heights. |
| The long-term impact of increased pacemaker use, paravalvular regurgitation, and durability concerns associated with transcatheter heart valves is still unknown. |
| Leaflet thickening and future coronary re-access remain significant concerns with TAVR. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.